‹³Žö@–î–ì@ˆçŽq@(Ikuko Yano, Ph.D.)

@
og
@•ºŒÉŒ§
@
Š‘®Šw‰ï
@American Society for Clinical Pharmacology and Therapeutics
@International Association of Therapeutic Drug Monitoring and Clinical
Toxicology (IATDMCT)
@“ú–{–òŠw‰ï
@“ú–{ˆã—ÖòŠw‰ïi‘ã‹cˆõEŠw‰ï”F’èŽw“±–òÜŽtj
@“ú–{—Õ°–ò—Šw‰ïiŽÐˆõEŠw‰ï”F’èŽw“±–òÜŽtj
@“ú–{TDMŠw‰ïi•]‹cˆõj
@“ú–{–ò•¨“®‘ÔŠw‰ïi•]‹cˆõj
y‹³Žö@‘呺@—F”Ž@iTomohiro Omura, Ph.D.j
@og
@–kŠC“¹
@
Š‘®Šw‰ï
@“ú–{_Œo‰»Šw‰ï
@“ú–{–òŠw‰ï
@“ú–{ˆã—ÖòŠw‰ïiŠw‰ï”F’èŽw“±–òÜŽtj
@Society for Neuroscience
@“ú–{—Õ°ŽîᇖòŠw‰ï
uŽt@ŽR–{@˜aG@iKazuhiro Yamamoto, Ph.D.j

@og
@“Þ—ÇŒ§
@
@Š‘®Šw‰ï
@International Association of Therapeutic Drug Monitoring and Clinical
Toxicology (IATDMCT)
@“ú–{–òŠw‰ï
@“ú–{ˆã—ÖòŠw‰ïi‘ã‹cˆõEŠw‰ï”F’èŽw“±–òÜŽtj
@“ú–{—Õ°–ò—Šw‰ï
@“ú–{TDMŠw‰ï
@“ú–{t‘Ÿ•a–ò•¨—Ö@Šw‰ïiŠw‰ïê–å–òÜŽtj
“Á–½•‹³@–kœA@—DŽÀiYumi Kitahiro, Ph.D.j

@og
@‘åã•{
@
Š‘®Šw‰ï
@“ú–{ˆã—ÖòŠw‰ï
@“ú–{–òŠw‰ï
“Á–½•‹³@Ž…Œ´@Œõ‘¾˜YiKotaro Itohara, Ph.D.j
@og
@“‡ªŒ§
@
@Š‘®Šw‰ï
@International Association of Therapeutic Drug Monitoring and Clinical
Toxicology (IATDMCT)
@“ú–{–òŠw‰ï
@“ú–{ˆã—ÖòŠw‰ï
@“ú–{—Õ°–ò—Šw‰ï
@“ú–{TDMŠw‰ï
@“ú–{–ò•¨“®‘ÔŠw‰ï
@“ú–{‰»Šw—Ö@Šw‰ï
‘åŠw‰@¶
- ãã@—Ïs
- _ŒË‘åŠw‘åŠw‰@ˆãŠwŒ¤‹†‰Èˆã‰ÈŠwêUiŽÐ‰ïl”ŽŽm‰Û’öj
- –x@’q‹M
- _ŒË‘åŠw‘åŠw‰@ˆãŠwŒ¤‹†‰Èˆã‰ÈŠwêUiŽÐ‰ïl”ŽŽm‰Û’öj
- ¬¼@—Y‰î
- _ŒË‘åŠw‘åŠw‰@ˆãŠwŒ¤‹†‰Èˆã‰ÈŠwêUiŽÐ‰ïl”ŽŽm‰Û’öj
- ¼Œû@‘å¶
- _ŒË‘åŠw‘åŠw‰@ˆãŠwŒ¤‹†‰Èˆã‰ÈŠwêUi”ŽŽm‰Û’öj
- –쑺@ŒŽ
- _ŒË‘åŠw‘åŠw‰@ˆãŠwŒ¤‹†‰Èˆã‰ÈŠwêUi”ŽŽm‰Û’öj
- ˆÉ’n’m@•Žj
- _ŒË‘åŠw‘åŠw‰@ˆãŠwŒ¤‹†‰Èˆã‰ÈŠwêUiƒoƒCƒIƒƒfƒBƒJƒ‹ƒTƒCƒGƒ“ƒXj
- ¬ŽR@O‰Ô
- _ŒË‘åŠw‘åŠw‰@ˆãŠwŒ¤‹†‰Èˆã‰ÈŠwêUiƒoƒCƒIƒƒfƒBƒJƒ‹ƒTƒCƒGƒ“ƒXj
Šw•”¶
- ‚‹´@‘å
- _ŒË–ò‰È‘åŠw@–òŠw—Õ°‹³ˆçƒZƒ“ƒ^[
- ’·’Jì@•‘
- _ŒË–ò‰È‘åŠw@–òŠw—Õ°‹³ˆçƒZƒ“ƒ^[
- ‘ì@—´”V‰î
- _ŒË–ò‰È‘åŠw@–òŠw—Õ°‹³ˆçƒZƒ“ƒ^[
- ‘OŽR@k‹K
- _ŒË–ò‰È‘åŠw@–òŠw—Õ°‹³ˆçƒZƒ“ƒ^[
- Žð–Ø@‹I•ä
- _ŒË–ò‰È‘åŠw@ˆã–ò•iî•ñŠwŒ¤‹†Žº
- ‘¾“c@‚©‚È‚é
- _ŒË–ò‰È‘åŠw@–òŠw—Õ°‹³ˆçƒZƒ“ƒ^[
- •y‰ª@“Þ‰›
- _ŒË–ò‰È‘åŠw@–òŠw—Õ°‹³ˆçƒZƒ“ƒ^[
- ‘D‹´@÷Žq
- _ŒË–ò‰È‘åŠw@ˆã–ò•iî•ñŠwŒ¤‹†Žº









